Suppr超能文献

肝脏和肠道胆固醇调节酶的变化。二甲双胍的影响。

Changes in hepatic and intestinal cholesterol regulatory enzymes. The influence of metformin.

作者信息

Scott L M, Tomkin G H

出版信息

Biochem Pharmacol. 1983 Mar 1;32(5):827-30. doi: 10.1016/0006-2952(83)90583-x.

Abstract

The effect of metformin (N,N-dimethylbiguanide) on the rate-limiting enzymes of cholesterol metabolism was observed. 3-Hydroxy-3-methylglutaryl-CoA reductase (HMG-CoA reductase) and acyl-CoA-cholesterol acyltransferase (ACAT) activities were estimated in hepatic microsomal and intestinal cell preparations from normal and alloxan-diabetic rats. Metformin administration had no effect on either hepatic enzyme. Intestinal ACAT activity was significantly decreased in the metformin-treated rats when compared with controls (P less than 0.001). Intestinal HMG-CoA reductase activity was not significantly affected. Diabetic rats showed a significantly higher intestinal HMG-CoA reductase activity when compared with controls (P less than 0.001). Intestinal ACAT activity in the diabetic group was similar to control values. Metformin administration to diabetic rats caused a marked decrease in both intestinal HMG-CoA reductase activity (P less than 0.001) and ACAT activity (P less than 0.002). It is concluded that the effect of metformin on the intestinal cholesterol enzyme system may be responsible for its cholesterol-lowering action.

摘要

观察了二甲双胍(N,N - 二甲基双胍)对胆固醇代谢限速酶的影响。在正常大鼠和四氧嘧啶糖尿病大鼠的肝微粒体及肠细胞制剂中,评估了3 - 羟基 - 3 - 甲基戊二酰辅酶A还原酶(HMG - CoA还原酶)和酰基辅酶A - 胆固醇酰基转移酶(ACAT)的活性。给予二甲双胍对两种肝脏酶均无影响。与对照组相比,二甲双胍治疗的大鼠肠ACAT活性显著降低(P < 0.001)。肠HMG - CoA还原酶活性未受到显著影响。与对照组相比,糖尿病大鼠的肠HMG - CoA还原酶活性显著更高(P < 0.001)。糖尿病组的肠ACAT活性与对照值相似。给糖尿病大鼠服用二甲双胍导致肠HMG - CoA还原酶活性(P < 0.001)和ACAT活性(P < 0.002)均显著降低。得出结论,二甲双胍对肠道胆固醇酶系统的作用可能是其降低胆固醇作用的原因。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验